Checkpoint TherapeuticsCKPT
CKPT
About: Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
Employees: 23
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
267% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 6
38% more call options, than puts
Call options by funds: $694K | Put options by funds: $503K
36% more capital invested
Capital invested by funds: $12.6M [Q2] → $17.2M (+$4.54M) [Q3]
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
5% more funds holding
Funds holding: 44 [Q2] → 46 (+2) [Q3]
1.08% more ownership
Funds ownership: 16.26% [Q2] → 17.33% (+1.08%) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$7
87%
upside
Avg. target
$13.50
260%
upside
High target
$20
433%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Lake Street Thomas Flaten 33% 1-year accuracy 3 / 9 met price target | 87%upside $7 | Buy Maintained | 16 Dec 2024 |
HC Wainwright & Co. Joseph Pantginis 21% 1-year accuracy 79 / 384 met price target | 433%upside $20 | Buy Reiterated | 16 Dec 2024 |
Financial journalist opinion
Positive
Seeking Alpha
3 days ago
Checkpoint Therapeutics: Updating My Strategy After Unloxcyt's Approval
Checkpoint Therapeutics, Inc. received FDA approval for Unloxcyt, the first PD-L1 drug for advanced cSCC, with strong clinical results and a market-disruptive pricing strategy. Despite mixed investor reactions, Unloxcyt's potential $1.6B peak sales and competitive pricing could make it a transformative player in the cSCC market. Risks include high competition, commercialization costs, and potential IP challenges, but Checkpoint's strategic partnerships and marketing are crucial for success.
Neutral
GlobeNewsWire
1 week ago
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)
UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma
Positive
Seeking Alpha
1 month ago
Checkpoint Therapeutics: Preparing For Cosibelimab's Upcoming PDUFA Date
Checkpoint Therapeutics, Inc.'s cosibelimab shows promising efficacy and safety in treating cSCC, with a high tumor occupancy rate and strong clinical data. The upcoming PDUFA date on December 28th is crucial, with potential FDA approval driving significant market growth and revenue projections. Despite competitive pressures and financial risks, cosibelimab's unique mechanism and strong IP position offer substantial market opportunities in cSCC and beyond.
Neutral
GlobeNewsWire
1 month ago
Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
Biologics License Application for cosibelimab under review by U.S. FDA PDUFA goal date of December 28, 2024 WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the third quarter ended September 30, 2024, and recent corporate updates.
Neutral
GlobeNewsWire
3 months ago
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024
Biologics License Application currently under review by U.S. FDA; PDUFA goal date of December 28, 2024 Biologics License Application currently under review by U.S. FDA; PDUFA goal date of December 28, 2024
Neutral
GlobeNewsWire
3 months ago
Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
WALTHAM, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 10, 2024, at 10:00 a.m. ET. The Company will also attend in-person and virtual one-on-one meetings during the conference.
Positive
Seeking Alpha
3 months ago
Checkpoint Therapeutics: A Binary Bet On FDA Approval And Cosibelimab's Market Success
Checkpoint Therapeutics' Cosibelimab, an anti-PD-L1 antibody, shows promise for treating cSCC, with potential FDA approval by December 2024, making CKPT a speculative "buy." Cosibelimab's dual mechanism of action, engaging both T cells and NK cells, offers a competitive edge over other PD-L1 inhibitors, enhancing its efficacy. Despite CKPT's low cash reserves and regulatory risks, the potential market for Cosibelimab in cSCC treatment is estimated at over $1 billion in the US.
Positive
Zacks Investment Research
4 months ago
What Makes Checkpoint Therapeutics (CKPT) a New Buy Stock
Checkpoint Therapeutics (CKPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
GlobeNewsWire
4 months ago
Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates
WALTHAM, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the second quarter ended June 30, 2024, and recent corporate updates.
Neutral
GlobeNewsWire
4 months ago
Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
WALTHAM, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review Checkpoint's resubmission of its Biologics License Application (“BLA”) for cosibelimab, its anti-programmed death ligand-1 (“PD-L1”) antibody, as a potential new treatment for adults with metastatic or locally advanced cutaneous squamous cell carcinoma (“cSCC”) who are not candidates for curative surgery or curative radiation.
Charts implemented using Lightweight Charts™